Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization.

Cancer Cell 2010 Dec 2;18(6):630-40. Epub 2010 Dec 2.

Institute for Molecular Medicine Finland, Department of Pathology, Haartman Institute, Helsinki University Central Hospital, University of Helsinki, Finland.

Antibodies that block vascular endothelial growth factor (VEGF) have become an integral part of antiangiogenic tumor therapy, and antibodies targeting other VEGFs and receptors (VEGFRs) are in clinical trials. Typically receptor-blocking antibodies are targeted to the VEGFR ligand-binding site. Here we describe a monoclonal antibody that inhibits VEGFR-3 homodimer and VEGFR-3/VEGFR-2 heterodimer formation, signal transduction, as well as ligand-induced migration and sprouting of microvascular endothelial cells. Importantly, we show that combined use of antibodies blocking ligand binding and receptor dimerization improves VEGFR inhibition and results in stronger inhibition of endothelial sprouting and vascular network formation in vivo. These results suggest that receptor dimerization inhibitors could be used to enhance antiangiogenic activity of antibodies blocking ligand binding in tumor therapy.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccr.2010.11.001DOI Listing
December 2010
13 Reads

Publication Analysis

Top Keywords

ligand binding
12
antibodies blocking
12
receptor dimerization
12
network formation
8
blocking ligand
8
vascular network
8
binding receptor
8
tumor therapy
8
antibodies
6
inhibition stronger
4
receptor-blocking antibodies
4
typically receptor-blocking
4
vegfr ligand-binding
4
inhibition endothelial
4
endothelial sprouting
4
stronger inhibition
4
antibodies targeted
4
targeted vegfr
4
clinical trials
4
receptors vegfrs
4

Similar Publications